All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AB8939
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The therapeutic potential of AB8939 in AML is demonstrated using Ara-C resistant and azacitidine resistant patient-derived xenograft (PDX) models.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BiCKI-IL-7
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The AACR update presentations show that BiCKI®-IL-7 will help overcome resistance mechanisms to anti-PD(L)-1 therapies and could potentially address the needs of a patient population in immune escape from checkpoint inhibitor treatment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Anti-CLEC-1 monoclonal antibody
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
OSE Immunotherapeutics’ poster presentation featured CLEC-1 antagonist monoclonal antibodies, which have been identified as an innovative immunotherapy that releases the brakes on macrophage phagocytosis and dendritic cells and demonstrates synergistic anti-cancer effects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
Details:
AACR abstract outlines the broad therapeutic potential of BT-001, an oncolytic virus encoding an anti-CTLA4 antibody.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): STI-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Portage Biotech
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Financing May 11, 2020
Details:
Stimunity has reached a major milestone in its preclinical development plan and the additional financing will enable it to start the manufacturing of its biologic cGAMP-VLP (STI-001) lead compound.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT-001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
Comprehensive data package supports pending clinical trial application for the first-in-human study of BT-001.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OX401
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Details:
The data will showcase the high affinity with PARP that leads to DDR inhibition, metabolic exhaustion and activation of the innate immune response, specifically in tumoral cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABD-3001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Xerys Funds
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Funding February 26, 2020
Details:
Advanced BioDesign will finalise its preclinical studies and submit a clinical trial authorization to start clinical phase I in AML in early 2021.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OX401
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 28, 2020
Details:
Onxeo is building a strong preclinical data set for OX401, optimized for both PARP inhibition and STING response as well as bypass resistance., as homologous recombination deficiency requirements.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): SKY01
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: French Tech Seed
Deal Size: $0.8 million Upfront Cash: Undisclosed
Deal Type: Funding January 20, 2020
Details:
These funds will allow the company to accelerate the development of its flagship drug candidate, before launching a new fundraising round that will address clinical trials.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
